Targeting Toxoplasma parasites and their protein accomplices
Toxoplasmosis is an infectious disease caused by the parasite Toxoplasma gondii and is transmitted via contaminated food or feces. The infection can cause a range of symptoms that may be mild or severe, resulting in blindness and brain infection. Current T. gondii therapeutics are not very effective, so scientists need to further investigate potential drug targets.
Sheena Dass and a team of researchers from the Université Grenoble Alpes, France, identified seven genes responsible for expressing enzymes of metabolic interest in these parasites. Their recent in the Journal of Lipid Research characterizes one of these enzymes, T. gondii acyl-CoA synthetase 3, or TgACS3.
TgACS3 was found to be localized in the cytosol of the parasite and to upregulate its parasitic growth while increasing its chances of survival within its host. Gas chromatography-mass spectrometry was implemented to analyze the lipid content in the parasite, which revealed the role of TgAC3 in the uptake and utilization of its host fatty acids, generating the parasite phospholipid layer, and maintaining the growth of new parasites.
This study is an important step towards achieving targeted therapeutic mechanisms in the treatment of Toxoplasmosis, as researchers can leverage the findings shared in a more rigorous analysis.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Early lipid changes drive retinal degeneration in Zellweger spectrum disorder
Lipid profiling in a rare disease mouse model reveals metabolic shifts and inflammation in the retinal pigment epithelium — offering promising biomarker leads to combat blindness.
How sugars shape Marfan syndrome
Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.
What’s in a diagnosis?
When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.
Peer through a window to the future of science
Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.
Glow-based assay sheds light on disease-causing mutations
University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.
How signals shape DNA via gene regulation
A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent ɬ paper.